Visipaque

Visipaque®

Iodixanol Imaging A nonionic radiocontrast Indications Intraarterial–eg, visceral intraarterial digital subtraction angiography, angiocardiography–eg, left ventriculography and selective coronary arteriography, peripheral arteriography, visceral arteriography, cerebral arteriography; IV injection for CECT–contrast-enhanced CT imaging of head and body, excretory urography, peripheral venography. See Radiocontract.
Mentioned in ?
References in periodicals archive ?
Contrast agent used was Visipaque at a dose of 1 mL/kg body weight, injected through the median cubital vein with a rate of 4.
We hypothesized that this sample was contaminated with Visipaque (3), a contrast medium used in computed tomography--guided SVS that can increase plasma density (4).
Giles, UK: GE Healthcare today announced results from an independent study, which showed that use of isosmolar contrast agent Visipaque 320 (iodixanol 320mg I/ml) provides better image quality of coronary stents during multi-detector CT coronary angiography (MDCT-CA) than use of Iomeron 400 (iomeprol 400mg l/ml) when injected at the same flow rate (5.
Claims on the website "misleadingly suggest that Visipaque offers a safety benefit compared to other products due to its unique formulation," the FDA said.
Products include Visipaque, which helps show up features such as veins in x-rays.
Amersham, which makes products for disease detec- ti on and medical research, said its ``fundamentals'' remained strong with a surge in sales of its marker product Visipaque - which helps show up features such as veins in X-rays -after positive safety data.
The global market will witness a growth at 5% Compounded Annual Growth Rate (CAGR) due to patent expiry of leading contrast agents such as Myoview and Visipaque in 2010-2011, consequent entry of generics, declining reimbursement and adverse clinical studies associated with contrast agents.
Princeton, NJ: GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque (iodixanol 320mg I/ml) were less likely to experience discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue (iopamidol 370 mg I/ml).
The most commonly used contrast media in our hospital are two nonionic contrast media, Omnipaque (iohexol; 350 g/L iodine; Nycomed) and Visipaque (iodixanol; 320 g/L iodine; Nycomed), and to a much lesser extent, two ionic contrast media, Telebrix[R] (sodium meglumine ioxithalamate; 350 g/L iodine; Guerbet) and Urografin[R] (sodium meglumine diatrizoate; 146 g/L iodine; Schering).
Finally, it is well within the public interest for this Court to enjoin GEH from disseminating false messages regarding Visipaque.